Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03453489 · ClinicalTrials.gov registry record · Phase 2
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
A Phase 2 study of Carcinoid Syndrome and Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT03453489 is a Phase 2 study of Carcinoid Syndrome and Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 4 participants, below the 143-participant average among 4 other Carcinoid Syndrome trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03453489, a Phase 2 study of Carcinoid Syndrome and Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying the changes within the tumor cells via AMT-PET may help doctors better understand how tumors respond to treatment with telotristat etiprate.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Laboratory Biomarker Analysis
- DRUG Telotristat Etiprate
- OTHER Carbon C 11 Alpha-methyltryptophan
Study Locations (1)
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03453489
The ClinicalTrials.gov registry entry for NCT03453489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 4 other Carcinoid Syndrome trials with a reported enrollment target (97% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoid Syndrome appearing as the primary indexed condition, and to 4 interventions - of which Positron Emission Tomography is the first listed.
NCT03453489 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03453489 about?
NCT03453489 is a clinical study titled "AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm". This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the gr...
What is the current status of trial NCT03453489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-06-20. Estimated completion is 2020-10-15.
What conditions does trial NCT03453489 study?
This clinical trial studies the following conditions: Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm.
What interventions are being tested in trial NCT03453489?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Telotristat Etiprate (DRUG), Carbon C 11 Alpha-methyltryptophan (OTHER).
Who is sponsoring clinical trial NCT03453489?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03453489 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoid Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
RECRUITING · Phase 3
-
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
COMPLETED
-
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
COMPLETED · Phase 3
Explore more on PlainTrial
Carcinoid Syndrome
All registered trials for this condition
Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.